Abstract
Our previous study indicated that nontoxic doses of quercetin (Que) could increase the chemosensitivity of breast cancer cells to doxorubicin (Dox) although the mechanism still remains elusive. Therefore, in this study, we aimed to investigate the underlying mechanisms. MCF-7 cells and MCF-7/dox cells were exposed to PTEN inhibitor bpV (HOpic), Dox, or combination of Dox and Que with or without bpV (HOpic) intervention for 24 hours. Cell proliferation, cell apoptosis, cell invasion and expression of PTEN and phospho-Akt (p-Akt) were then assessed. bpV (HOpic) had little effect on cell proliferation at concentrations less than 1 μM. Compared to treatment with Dox alone, combined treatment with Dox and Que significantly inhibited cell proliferation and invasion, increased cell apoptosis, up-regulated the expression of PTEN and down-regulated the expression of p-Akt. However, co-treatment with PTEN inhibitor bpV (HOpic) could revert the effects of Que on Dox. These data indicate that Que can increase the sensitivity of breast cancer cells to Dox through down regulation of p-Akt expression arising from increased expression of PTEN.
Keywords: Chemosensitivity, doxorubicin, p-Akt, PTEN, quercetin.
Anti-Cancer Agents in Medicinal Chemistry
Title:Quercetin Increase the Chemosensitivity of Breast Cancer Cells to Doxorubicin Via PTEN/Akt Pathway
Volume: 15 Issue: 9
Author(s): Shi-zheng Li, Shi-feng Qiao, Jun-hua Zhang and Kun Li
Affiliation:
Keywords: Chemosensitivity, doxorubicin, p-Akt, PTEN, quercetin.
Abstract: Our previous study indicated that nontoxic doses of quercetin (Que) could increase the chemosensitivity of breast cancer cells to doxorubicin (Dox) although the mechanism still remains elusive. Therefore, in this study, we aimed to investigate the underlying mechanisms. MCF-7 cells and MCF-7/dox cells were exposed to PTEN inhibitor bpV (HOpic), Dox, or combination of Dox and Que with or without bpV (HOpic) intervention for 24 hours. Cell proliferation, cell apoptosis, cell invasion and expression of PTEN and phospho-Akt (p-Akt) were then assessed. bpV (HOpic) had little effect on cell proliferation at concentrations less than 1 μM. Compared to treatment with Dox alone, combined treatment with Dox and Que significantly inhibited cell proliferation and invasion, increased cell apoptosis, up-regulated the expression of PTEN and down-regulated the expression of p-Akt. However, co-treatment with PTEN inhibitor bpV (HOpic) could revert the effects of Que on Dox. These data indicate that Que can increase the sensitivity of breast cancer cells to Dox through down regulation of p-Akt expression arising from increased expression of PTEN.
Export Options
About this article
Cite this article as:
Li Shi-zheng, Qiao Shi-feng, Zhang Jun-hua and Li Kun, Quercetin Increase the Chemosensitivity of Breast Cancer Cells to Doxorubicin Via PTEN/Akt Pathway, Anti-Cancer Agents in Medicinal Chemistry 2015; 15 (9) . https://dx.doi.org/10.2174/1871520615999150121121708
DOI https://dx.doi.org/10.2174/1871520615999150121121708 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cyclin-Dependent Kinase Inhibitors as Anticancer Drugs
Current Drug Targets Distribution, Bioactivities and Therapeutical Potentials of Pentagalloylglucopyranose
Current Bioactive Compounds Clinical Next Generation Sequencing for Precision Medicine in Cancer
Current Genomics Screening and Partial Purification of Cholinesterase Inhibitor from Microalgae
Current Enzyme Inhibition Cell Cycle Arrest as a Therapeutic Target of Acute Kidney Injury
Current Protein & Peptide Science The Immunomodulating Activities of Resveratrol Glucosides in Humans
Recent Patents on Food, Nutrition & Agriculture PPARγ-targeting Potential for Radioprotection
Current Drug Targets Oncolytic Viruses: Programmable Tumour Hunters
Current Gene Therapy Brain-Derived Neurotrophic Factor (BDNF) has Proliferative Effects on Neural Stem Cells through the Truncated TRK-B Receptor, MAP Kinase, AKT, and STAT-3 Signaling Pathways
Current Neurovascular Research Therapeutic Manipulation of the Immune System: Enhancement of Innate and Adaptive Mucosal Immunity
Current Pharmaceutical Design Antibody Targeting of TGF-β in Cancer Patients
Current Pharmaceutical Biotechnology Role of Integrated 18-F FDG PET/CT in Recurrent Ovarian Cancer
Current Medical Imaging Pharmacokinetic and Toxicological Characteristics of Tripterigium Glycosides and Their Derivatives
Current Drug Metabolism Gold and Silver Nanoparticles for Applications in Theranostics
Current Topics in Medicinal Chemistry COX-2 and Colorectal Cancer
Current Pharmaceutical Design lncRNAs as Potential Targets in Small Cell Lung Cancer: MYC -dependent Regulation
Anti-Cancer Agents in Medicinal Chemistry Targeting Molecular Imaging Approach for Detection of Infection and Inflammation by Diagnostic Nuclear Medicine Techniques
Current Medical Imaging Pharmacology and Therapeutic Applications of A3 Receptor Subtype
Current Topics in Medicinal Chemistry Protein Microarrays for Studies of Drug Mechanisms and Biomarker Discovery in the Era of Systems Biology
Current Pharmaceutical Design Vitamin D: Evolutionary, Physiological and Health Perspectives
Current Drug Targets